Table 1.
Serum tumor markers in bilharzial and non-bilharzial bladder cancer patients compared to normal (unaffected) patients
| Parameters | Control | Bilharzial bladder cancer patients |
non-bilharzial bladder cancer patients |
ANOVA P < |
|---|---|---|---|---|
| 1. XO (μmol uric acid/min/ml) LSD |
0.3 ± 0.05 (2,3) |
2.77 ± 0.33 (1,3) |
1.58 ± 0.23 (1,2) |
P < 0.0001 |
| 2. Fructosamine (μmol/L) LSD |
337.88 ± 34.4 (2,3) |
1145.27 ± 146.16 (1,3) |
742.3 ± 132.44 (1,2) |
P < 0.0001 |
| 3. hydroxylproline (μg/ml) LSD |
23.35 ± 2.83 (2,3) |
78.56 ± 10.48 (1,3) |
46.06 ± 4.28 (1,2) |
P < 0.0001 |
| 4. IgE (IU/ml) LSD |
44.37 ± 1.66 (2,3) |
301.49 ± 14.04 (1,3) |
269.0 ± 7.66 (1,2) |
P < 0.0001 |
| 5. TNF-∝ (Pg/ml) LSD |
7.8 ± 0.22 (2,3) |
37.7 ± 1.61 (1,3) |
24.6 ± 0.84 (1,2) |
P < 0.0001 |
Data are represented as mean ± SD of 10 control and 30 patients (15 patients bilharzial and 15 non-bilharzial)